Research progress and prospects of neoadjuvant endocrine therapy for breast cancer

Neoadjuvant endocrine therapy (NET) instead of neoadjuvant chemotherapy (NCT) is an effective clinical strategy for estrogen receptor (ER)-positive breast cancer patients, which can reduce tumor stage, achieve breast-conserving surgery for breast cancer and reduce the need for adjuvant chemotherapy....

Full description

Bibliographic Details
Main Author: QIAN Yao, LIU Feng
Format: Article
Language:English
Published: Editorial Office of China Oncology 2022-07-01
Series:Zhongguo aizheng zazhi
Subjects:
Online Access:http://www.china-oncology.com/fileup/1007-3639/PDF/1660021600059-360286874.pdf
_version_ 1798001878485696512
author QIAN Yao, LIU Feng
author_facet QIAN Yao, LIU Feng
author_sort QIAN Yao, LIU Feng
collection DOAJ
description Neoadjuvant endocrine therapy (NET) instead of neoadjuvant chemotherapy (NCT) is an effective clinical strategy for estrogen receptor (ER)-positive breast cancer patients, which can reduce tumor stage, achieve breast-conserving surgery for breast cancer and reduce the need for adjuvant chemotherapy. This article aimed to review the latest research progress in several aeras: patient selection for NET, comparison of efficacy of NET, duration of NET, comparison and combined use of NET and NCT, NET combined with targeted therapy, window of opportunity trials, efficacy evaluation indicators and adjuvant therapy decision after neoadjuvant endocrine therapy.
first_indexed 2024-04-11T11:43:05Z
format Article
id doaj.art-3ffa793b807342a3842094bca9854b9e
institution Directory Open Access Journal
issn 1007-3639
language English
last_indexed 2024-04-11T11:43:05Z
publishDate 2022-07-01
publisher Editorial Office of China Oncology
record_format Article
series Zhongguo aizheng zazhi
spelling doaj.art-3ffa793b807342a3842094bca9854b9e2022-12-22T04:25:45ZengEditorial Office of China OncologyZhongguo aizheng zazhi1007-36392022-07-0132764364910.19401/j.cnki.1007-3639.2022.07.008Research progress and prospects of neoadjuvant endocrine therapy for breast cancerQIAN Yao, LIU Feng0Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, Heilongjiang Province, ChinaNeoadjuvant endocrine therapy (NET) instead of neoadjuvant chemotherapy (NCT) is an effective clinical strategy for estrogen receptor (ER)-positive breast cancer patients, which can reduce tumor stage, achieve breast-conserving surgery for breast cancer and reduce the need for adjuvant chemotherapy. This article aimed to review the latest research progress in several aeras: patient selection for NET, comparison of efficacy of NET, duration of NET, comparison and combined use of NET and NCT, NET combined with targeted therapy, window of opportunity trials, efficacy evaluation indicators and adjuvant therapy decision after neoadjuvant endocrine therapy.http://www.china-oncology.com/fileup/1007-3639/PDF/1660021600059-360286874.pdf|breast cancer|neoadjuvant endocrine therapy|prognosis
spellingShingle QIAN Yao, LIU Feng
Research progress and prospects of neoadjuvant endocrine therapy for breast cancer
Zhongguo aizheng zazhi
|breast cancer|neoadjuvant endocrine therapy|prognosis
title Research progress and prospects of neoadjuvant endocrine therapy for breast cancer
title_full Research progress and prospects of neoadjuvant endocrine therapy for breast cancer
title_fullStr Research progress and prospects of neoadjuvant endocrine therapy for breast cancer
title_full_unstemmed Research progress and prospects of neoadjuvant endocrine therapy for breast cancer
title_short Research progress and prospects of neoadjuvant endocrine therapy for breast cancer
title_sort research progress and prospects of neoadjuvant endocrine therapy for breast cancer
topic |breast cancer|neoadjuvant endocrine therapy|prognosis
url http://www.china-oncology.com/fileup/1007-3639/PDF/1660021600059-360286874.pdf
work_keys_str_mv AT qianyaoliufeng researchprogressandprospectsofneoadjuvantendocrinetherapyforbreastcancer